CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Last trade$19.91
Day change+$0.11 (+0.56%)
Day range$19.34 – $20.29
Volume441,145
Market cap$1.00B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1B
Price / earnings
—
Price / book
2.07×
Price / sales
5.21×
EV / sales
4.74×
EV / EBITDA
-71.94×
Profitability
Earnings per share
-$0.97
Return on assets
-6.56%
Return on equity
-10.2%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.39×
Current ratio
2.04×
Quick ratio
1.94×
Cash ratio
1.25×
Cash flow
Price / cash flow
91.18×
Price / free cash flow
—
Free cash flow
-$18.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CYRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$50.22M
$48.97M
$47.8M
$45.45M
$44.23M
$45.45M
$41.04M
$41.45M
Cost of revenue
$26.39M
$26.15M
$25.89M
$23.74M
$22.91M
$24.08M
$22.4M
$21.96M
Gross profit
$23.83M
$22.82M
$21.91M
$21.71M
$21.33M
$21.38M
$18.64M
$19.49M
Selling, general and administrative
$27.9M
$28.01M
$27.62M
$27.28M
$26.73M
$26.91M
$21.9M
$28.08M
Research and development
$4.73M
$4.85M
$3.91M
$4.47M
$4.52M
$4.12M
$3.93M
$4.16M
Total operating expenses
$32.64M
$32.86M
$31.53M
$31.74M
$31.26M
$31.03M
$25.84M
$32.24M
Operating income
-$8.8M
-$10.04M
-$9.61M
-$10.03M
-$9.93M
-$9.65M
-$7.19M
-$12.75M
Interest expense
-$517K
-$518K
-$432K
-$634K
-$526K
-$618K
-$583K
-$579K
Income before taxes
-$10.66M
-$7.75M
-$9.32M
-$7.4M
-$6.53M
-$11.74M
-$6.5M
-$17.31M
Income taxes
$194K
$505K
$108K
$1.13M
$165K
$274K
$234K
-$134K
Net income
-$10.85M
-$8.26M
-$10.54M
-$11.64M
-$6.94M
$108.87M
-$11.98M
-$18.68M
Net income attributable to common shareholders
-$12.85M
-$10.26M
-$12.54M
-$13.64M
-$8.94M
$106.87M
-$13.98M
-$20.68M
EBITDA
-$2.34M
-$3.45M
-$3.21M
-$3.68M
-$3.52M
-$2.35M
$452K
-$4.85M
Basic earnings per share
-$0.25
-$0.20
-$0.25
-$0.27
-$0.18
$2.13
-$0.28
-$0.42
Diluted earnings per share
-$0.25
-$0.20
-$0.25
-$0.27
-$0.18
$2.13
-$0.28
-$0.42
Recent news
Company coverage with links to the original publishers.
CryoPort (CYRX) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19 loss by 31.58%. However, the company exceeded revenue expectations with $50.22 million versus the estimate of $48.68 million. The stock has gained 74% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Cencora reported Q3 2026 earnings of $4.66 per share, beating consensus estimates of $4.56, with revenues of $88.35 billion slightly exceeding expectations. The company has outperformed consensus EPS estimates three times over the last four quarters. Despite underperforming the S&P 500 year-to-date, Cencora received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. The Medical Services industry ranks in the top 45% of Zacks industries.
CryoPort, Inc. (CYRX) has returned 81.3% year-to-date, significantly outperforming the Medical sector's 1.6% average return. The company holds a Zacks Rank #2 (Buy) with improving earnings outlook. Delcath Systems, Inc. (DCTH) has also outperformed with a 58.1% year-to-date return and a Zacks Rank #1 (Strong Buy), supported by an 80.7% increase in consensus EPS estimates over three months.
Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised full-year 2026 revenue guidance to $192-196 million and reported improved adjusted EBITDA from continuing operations.
The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.